Evidence map›Paper›PMID 38001688›Full record

ArticleCancers2023

Side Effects from Cancer Therapies and Perspective of 1044 Long-Term Ovarian Cancer Survivors-Results of Expression VI-Carolin Meets HANNA-Holistic Analysis of Long-Term Survival with Ovarian Cancer: The International NOGGO, ENGOT, and GCIG Survey.

Hannah Woopen, Maren Keller, Dario Zocholl, Suzana Mittelstadt, Maria-Pilar Barretina-Ginesta, Viola Heinzelmann-Schwarz, Judith Lafleur, Roman Kocián, Joanna Baum, Petra Krabisch and 12 more

Abstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Needs and opportunities for improvement in the management and monitoring of gynaecological cancer in Spain.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  5. Article
  6. COVID-19 mortality risk among women with ovarian cancer: a matched case-control study.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 2026
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Hannah WoopenDepartment of Gynecology with Center for Oncological Surgery, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.ORCID 0000-0002-8617-5535
Maren KellerNorth-Eastern German Society for Gynecological Oncology (NOGGO), 13359 Berlin, Germany.
Dario ZochollNorth-Eastern German Society for Gynecological Oncology (NOGGO), 13359 Berlin, Germany.ORCID 0000-0002-9218-6919
Suzana MittelstadtNorth-Eastern German Society for Gynecological Oncology (NOGGO), 13359 Berlin, Germany.
Maria-Pilar Barretina-GinestaInstitut Català d'Oncologia, Medical Oncology Department, 17007 Girona, Spain.
Viola Heinzelmann-SchwarzDepartment of Gynecology and Gynecologic Oncology, University Hospital of Basel, 4056 Basel, Switzerland.
Judith LafleurDepartment of Gynecology and Obstetrics, Ordensklinikum Barmherzige Schwestern Linz, 4020 Linz, Austria.
Roman KociánDepartment of Gynaecology, Obstetrics and Neonatology First Faculty of Medicine, Charles University and General University Hospital in Prague, 12 108 Prague, Czech Republic.ORCID 0000-0002-5896-4158
Joanna BaumDepartment of Gynecology with Center for Oncological Surgery, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.
Petra KrabischNorth-Eastern German Society for Gynecological Oncology (NOGGO), 13359 Berlin, Germany.
Patriciu Achimas-CadariuInstitute of Oncology Prof. Dr. I. Chiricuta Cluj-Napoca, University of Medicine and Pharmacy Iuliu Hatieganu, 400015 Cluj-Napoca, Romania.ORCID 0000-0001-9928-5883
Mehmet Ali VardarDepartment of Gynecologic Oncology, Cukurova University, 01250 Adana, Turkey.
Ignace VergoteDivision of Gynaecological Oncology, Leuven Cancer Institute, University Hospitals Leuven, 3000 Leuven, Belgium.ORCID 0000-0002-7589-8981
Sara NasserDepartment of Gynecology with Center for Oncological Surgery, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.ORCID 0000-0002-5719-7532
Theresa LinkNorth-Eastern German Society for Gynecological Oncology (NOGGO), 13359 Berlin, Germany.
Marta Gil-MartinGrupo Español de Investigación en Cáncer de Ovario (GEICO), 28003 Madrid, Spain.ORCID 0000-0002-8548-5355
Tibor A ZwimpferDepartment of Gynecology and Gynecologic Oncology, University Hospital of Basel, 4056 Basel, Switzerland.ORCID 0000-0002-1574-6572
Katharina LeitnerArbeitsgemeinschaft Gynaekologische Onkologie Austria (AGO Austria), 6020 Innsbruck, Austria.ORCID 0000-0002-9572-9114
Marcin JedrykaCentral and Eastern European Gynecologic Oncology Group (CEEGOG), 128 51 Prague, Czech Republic.ORCID 0000-0001-8935-0311
Tamara BoxlerFrauenklinik Fürth, 90766 Fürth, Germany.
Elena Ioana BraicuDepartment of Gynecology with Center for Oncological Surgery, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.
Jalid SehouliDepartment of Gynecology with Center for Oncological Surgery, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.ORCID 0000-0002-5963-6623

Funding

German Ovarian Cancer Foundation, AstraZenecaGmbH, Janssen-CilagGmbH, PfizerPharmaGmbH and Tesaro n.a.
6 · The paper itself

Abstract

The aim of this survey was to increase the knowledge on the characteristics and health concerns of long-term survivors (LTS; survival > 5 years) after ovarian cancer in order to tailor follow-up care. This international survey was initiated by the NOGGO and was made available to members of ENGOT and GCIG. The survey is anonymous and consists of 68 questions regarding sociodemographic, medical (cancer) history, health concerns including distress, long-term side effects, and lifestyle. For this analysis, 1044 LTS from 14 countries were recruited. In total, 58% were diagnosed with FIGO stage III/IV ovarian cancer and 43.4% developed recurrent disease, while 26.0% were receiving cancer treatment at the time of filling in the survey. LTS who survived 5-10 years self-estimated their health status as being significantly worse than LTS who survived more than 10 years (

Indexed as

follow-up carelong-term side effectsovarian cancersurvivorship: long-term survivors

Identifiers

PMID38001688
PMCPMC10670049

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.